The ALCOA+ framework – Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available – defines the globally accepted principles for ensuring data integrity. Yet South African inspections and sponsor audits continue to highlight weaknesses in record-keeping practices, electronic system controls, and staff awareness.
This article examines why data integrity is non-negotiable, the most common inspection findings in South Africa, how regulators assess data credibility in practice, and how organisations can embed ALCOA+ principles into daily operations for long-term compliance and trust.
Why Data Integrity Matters
- Patient safety: Inaccurate, incomplete, or manipulated data can allow unsafe products to reach patients or mask safety signals.
- Regulatory compliance: SAHPRA, EMA, and FDA expect strict adherence to data integrity standards across paper and electronic systems.
- Sponsor confidence: Global sponsors rely on South African data for regulatory submissions and global decision-making.
- Business continuity: Data integrity failures can lead to licence suspension, rejected dossiers, halted trials, and long-term reputational damage.
For South Africa to remain a trusted global partner in pharmaceutical manufacturing and clinical trials, data integrity must be embedded as a core operational discipline rather than treated as a documentation exercise.
What Inspectors and Sponsors Focus on During Data Integrity Reviews
During inspections, regulators and sponsors do not only assess whether data exists — they assess whether it can be trusted. Typical focus areas include:
- Whether records were created contemporaneously or retrospectively
- Whether individuals can be clearly identified for every data entry
- Whether original data is retained and accessible
- Whether electronic systems have secure access controls and audit trails
- Whether corrections follow controlled, transparent processes
Inspectors often interview staff to test whether ALCOA+ principles are understood in practice, not just written in SOPs.
Common Data Integrity Failures in South Africa
1. Backdated Entries
Finding: Staff enter data days after activities occur, often under operational pressure.
Impact: Undermines reliability and raises immediate red flags during inspections.
Prevention: Train staff to record data contemporaneously and enforce zero-tolerance for retrospective entries without documented justification.
2. Missing Raw Data
Finding: Laboratories discard or fail to archive original readings, relying only on summary reports.
Impact: Prevents independent verification of results.
Prevention: Retain all raw data and implement SOPs for secure archiving and controlled access.
3. Shared User Logins in Electronic Systems
Finding: Multiple staff using a single password or shared system credentials.
Impact: Eliminates accountability and traceability.
Prevention: Assign unique user IDs, define access roles, and enforce periodic access reviews.
4. Incomplete or Disabled Audit Trails
Finding: Electronic systems without functional audit trails or with audit features disabled.
Impact: Inspectors cannot verify changes or data history.
Prevention: Validate systems, enable audit trails, and routinely review audit logs.
5. Illegible or Altered Paper Records
Finding: Handwritten records that are unclear or corrected using correction fluid.
Impact: Records may be deemed unreliable or invalid.
Prevention: Train staff in good documentation practice, prohibit correction fluid, and require controlled amendments.
6. Poor Data Retention Practices
Finding: Missing or incomplete archives of historical records.
Impact: Non-compliance with retention requirements and inability to support inspections.
Prevention: Implement controlled archives, access logs, and disaster-recovery plans.
Case Example: Data Integrity Findings in South Africa
Recent regulatory and sponsor inspections highlighted repeated data integrity weaknesses, including backdated batch manufacturing records, missing original chromatograms in quality control laboratories, and shared electronic logins at clinical research sites.
In one case, a sponsor delayed global submission of clinical trial data until corrective actions were verified and independently reviewed. This example illustrates how data integrity lapses create not only regulatory risk but also commercial and scientific delays.
Implementing ALCOA+ in Daily Operations
- Attributable: Ensure all data is traceable to the individual generating it.
- Legible: Records must be clear, permanent, and readable.
- Contemporaneous: Record data at the time the activity occurs.
- Original: Retain original data in paper or electronic form.
- Accurate: Data must reflect reality without manipulation.
- Complete: Capture all data, including outliers and failures.
- Consistent: Apply uniform documentation practices.
- Enduring: Preserve records securely over time.
- Available: Ensure data is accessible for audits and inspections.
Roadmap for Data Integrity Compliance
- Develop a formal data integrity policy aligned with ALCOA+.
- Train all staff, including management, on data integrity expectations.
- Validate electronic systems and enforce role-based access.
- Conduct routine data integrity audits and audit-trail reviews.
- Investigate data lapses using root cause analysis.
- Hold leadership accountable for data integrity culture.
- Benchmark practices against global regulatory expectations.
Building a Culture of Data Integrity
Data integrity cannot be sustained by SOPs alone. Organisations must foster a culture where transparency, accountability, and accuracy are valued. Staff should be encouraged to report errors without fear, and good documentation practices should be recognised and reinforced.
Frequently Asked Questions
1. Is data integrity a specific regulatory requirement in South Africa?
Yes. SAHPRA expects compliance with data integrity principles across GMP, GDP, GCP, and pharmacovigilance activities, aligned with international regulatory standards.
2. Does ALCOA+ apply to both paper and electronic records?
Yes. ALCOA+ principles apply equally to handwritten records and electronic systems.
3. Can poor data integrity result in licence suspension?
Yes. Serious or systemic data integrity failures can lead to licence suspension, rejected submissions, or halted clinical trials.
4. How often should organisations audit data integrity?
Best practice is to include data integrity checks in routine internal audits and conduct targeted reviews at least annually.
5. Who is responsible for data integrity within an organisation?
While QA oversees compliance, data integrity is a shared responsibility across all functions, supported by leadership accountability.
Conclusion
Data integrity is the foundation of trust in medicines and clinical research. For South Africa’s pharmaceutical and clinical trial sectors, embedding ALCOA+ principles ensures patient safety, regulatory compliance, and long-term credibility.
By addressing common failures such as backdated entries, missing raw data, and shared system access, organisations can protect both their regulatory standing and global partnerships.
How GH Strategies Supports Data Integrity & ALCOA+ Compliance
GH Strategies supports pharmaceutical manufacturers, clinical research sites, and distributors in South Africa through structured data integrity programmes, ALCOA+ training, and inspection readiness support.